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In this issue, Giebel et al. [1] report on the status of hae-
mato-oncology in Poland. They summarise achievements 
and describe its current situation. Polish haematology is 
most certainly at a crossroads. There has been a changing 
of the guard. Within just a few years, the ‘baby boomer’ 
generation (those born shortly after World War II) has trans-
ferred practically all chair positions to a younger generation 
of doctors born in the late 1960s and the 1970s. This is 
the generation whose careers began after the change of 
Poland’s political and economic system. This generation 
will be responsible for developments in the field over the 
next 20–30 years.
Since the start of the 21st century, the number of Po-
lish haematologists has more than doubled, reaching 
now almost 500 fully trained specialists, with more than 
100 in training. There are haematology centres in all re-
gions (previously almost half of Poland’s 16 voivodships 
had none) but the greatest challenge is the rapidly gro-
wing number of patients. This is due to the ageing of so-
ciety and even more so to the increased effectiveness of 
therapy. Progress in haematology which now is almost 
instantaneously incorporated into practice is generating 
more and more people surviving with chronic disease 
who need services.
An interesting analysis of the survival of patients with 
various cancers was published by the Polish National In-
stitute of Public Health. The overall effects of cancer treat-
ment in Poland are inferior when compared to the countries 
of what we used to call ‘Western Europe’. However, there is 
one exception: leukemia. Poland, while not leading, is not 
far behind these latter countries [2]. Poland is one of the 
few countries in which bone marrow transplantation tech-
nology was independently developed, rather than being 
imported from abroad [3–6]. While this was largely due to 
necessity (development took place in the early 1980s when 
Poland was under martial law and foreign travel was not 
permitted), this is a clear demonstration of the innovative 
potential of Polish haematology.
Today, Poland has nearly closed the gap in the number 
of haematopoietic cell transplantations (1,848 transplan-
tations in 2019) between it and more developed countries, 
and has become a ‘superpower’ in terms of the number of 
registered potential donors of haematopoietic cells (almost 
1.8 million registered and typed people). This is a figure 
exceeded only by the US, Germany, and Brazil. Moreover, 
Poland has become the second of only two countries (the 
first being Germany) to provide more transplants to foreign 
patients than to its own (1,294 vs. 265 in 2019) [7, 8].
While Polish haematology centres participate actively in 
global clinical trials, there is still a limited number of trials 
initiated and designed in Poland. The Polish pharmaceuti-
cal industry is concentrated on the production of generic 
drugs, and the next step should include also some inno-
vative molecules. However, these have to be invented or 
discovered by the chemists!
The successful introduction of Polish-made cladribine 
has shown that Polish haematology is capable of designing 
and performing trials with the aim of introducing new drugs 
to clinical practice, when gaining early access to new mo-
lecules [9, 10]. Polish haematology is well integrated into 
European haematology, with Polish centres being very acti-
ve in the European Leukemia Net, the European Haemato-
logy Association, and the European Society for Blood and 
Marrow Transplantation.
The future depends both on encouraging further rese-
arch in Poland, and actively participating in international 
collaboration.
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